Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

Introduction: Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non-genetic mechanisms underlying osimertinib resista...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Takehiro Tozuka, MD, Rintaro Noro, MD, PhD, Keisuke Yoshida, PhD, Satoshi Takahashi, MD, PhD, Mariko Hirao, MD, Kuniko Matsuda, MD, Yasuhiro Kato, MD, Shinji Nakamichi, MD, PhD, Susumu Takeuchi, MD, PhD, Masaru Matsumoto, MD, PhD, Akihiko Miyanaga, MD, PhD, Shinobu Kunugi, MD, PhD, Kazufumi Honda, DDS, PhD, Jun Adachi, PhD, Masahiro Seike, MD, PhD
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2024-04-01
Seri Bilgileri:	JTO Clinical and Research Reports
Konular:	Non–small cell lung cancer EGFR Osimertinib Resistant Src FAK
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2666364324000389
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

Benzer Materyaller